Tele: 561.316.3330
Breaking Medical Device News

Tuesday, September 21, 2021


HomeSenseonics HoldingsEversense Bridge Patient Access Program Launched in the U.S.

Eversense Bridge Patient Access Program Launched in the U.S.

March 22, 2019

Eversense Bridge Patient Access Program is launched in the U.S. by Senseonics.  Under the program, patients can access the Eversense CGM System, the only long-term CGM that lasts up to 90 days, for only $99* plus the cost of the sensor placement by the healthcare provider.

“The Eversense Bridge Patient Access Program is an important strategic initiative with the goal of providing access to eligible patients who have high out-of-pocket costs, are waiting for a favorable coverage policy, or have been denied insurance coverage for Eversense,” said Tim Goodnow, President, and CEO of Senseonics. “Insurance companies unfamiliar with the newest approved diabetes technology may deny coverage for a wide range of insured patients who have come forward demanding this technology. We developed this program to reduce barriers for patients who seek access to this technology right away. Every patient who qualifies for the program will now have improved access to this innovative diabetes management technology.”

The  is a patient access program designed to assist patients with confirming their insurance benefits, obtaining pre-authorizations before the sensor placement, and working with their healthcare provider’s office to help patients with the appeals of denied claims. From start to finish, the Eversense Bridge Program has been created to help the healthcare providers and patients have easier access to Eversense CGM.

The Eversense CGM System is a unique alternative for continuous monitoring of glucose. It consists of a fluorescence-based sensor, a smart transmitter worn over the sensor to facilitate data communication, and a mobile app for displaying glucose values, trends, and alerts. Unlike traditional CGMs, Eversense is the first and only implantable CGM sensor in the United States and has the longest duration of up to 90 days. It features a smart transmitter that provides discreet, on-body vibratory alerts for high and low glucose and can be removed, recharged, and re-adhered without discarding the sensor. The sensor is inserted subcutaneously in the upper arm by a health care provider via a brief in-office procedure.

“I commend Senseonics for addressing the critical issue of access barriers to new medical technology. Diabetes equipment and supplies are very expensive for patients, often even with insurance coverage,” said Amy Tenderich, DiabetesMine journalist/blogger and a diabetes advocate. “I am currently on my second Eversense sensor. I chose to be reinserted based on the accuracy and convenience this system provides. I am happy that the Eversense Bridge Program will allow many more patients to access this useful new tool.”

Patients who are interested in getting started on Eversense through the Eversense Bridge Program can sign up at Physicians, nurse practitioners, or physician assistants interested in offering the Eversense CGM System for their patients can contact Senseonics at 844-SENSE4U (844-736-7348).

Additionally, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2018, which was filed with the Securities and Exchange Commission (SEC) on March 15, 2019, Senseonics’ audited consolidated financial statements contained an audit opinion from its independent registered public accounting firm that included an explanatory paragraph relating to Senseonics’ ability to continue as a going concern. This announcement is made pursuant to NYSE-American Company Guide Sections 401(h) and 610(b), which require a public announcement of the receipt of an audit opinion containing a going concern qualification. This announcement does not represent any change or amendment to Senseonics’ consolidated financial statements or to its Annual Report on Form 10-K for the year ended December 31, 2018.

* For a limited time, patients who meet the program’s eligibility requirements may receive financial assistance towards acquiring the Eversense CGM System (after making an initial $99 payment). The Eversense Bridge Program does not apply to sensor placement procedure fees from patients’ healthcare providers, however, and patients must discuss coverage and payment for sensor placement separately with their physician (or other health care provider). The Eversense Bridge Program is not available for patients insured through federal healthcare programs or residents of certain states. View full terms on the Senseonics website.

Medical Device News Magazine
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected


Don't Miss

FDA Authorizes Software that Can Help Identify Prostate Cancer

The software is called Paige Prostate and is compatible for use with slide images that have been digitized using a scanner.

Shannon Lantzy MedCrypt New VP of Consulting

"I met Shannon at a healthcare-related event several years ago and was immediately impressed with her passion and drive to move healthcare into a digital future," said Mike Kijewski, CEO of MedCrypt.

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

By using this website you agree to accept Medical Device News Magazine Privacy Policy